Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy

EJHaem Pub Date : 2025-06-13 DOI:10.1002/jha2.70078

Rafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Michael W. Drazer, Anand A. Patel

{"title":"Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy","authors":"Rafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Michael W. Drazer, Anand A. Patel","doi":"10.1002/jha2.70078","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VEN are limited.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70078","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VEN are limited.

Methods

We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN.

Results

Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation.

Conclusion

This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.

查看原文本刊更多论文

髓系肿瘤患者在既往Venetoclax治疗后化疗加Venetoclax治疗的结果

背景：急性髓性白血病（AML）或骨髓增生异常综合征（MDS）患者在接受低甲基化剂（HMA）和venetoclax （VEN）治疗后出现进展的结果很差。然而，先前HMA+VEN治疗后化疗和VEN （C+VEN）治疗的数据有限。方法选取18例AML或MDS/AML患者，在既往HMA+VEN后接受C+VEN治疗。结果7例（39%）患者实现完全缓解（CR）或CR伴不完全血液学恢复（CRi）， 6例（33%）患者行同种异体造血干细胞移植。结论本研究表明，对于HMA+VEN后的一部分患者，C+VEN可能是一种可行的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量